As a result of the relatively short duration of ROP and long antibody half-life in the vitreous chamber with the blood–retina barrier, the disease typically requires only one intravitreal administration of anti-VEGF antibodies in clinical trials [12,36]. Here, VEGFA is linked to retinopathy of prematurity.